With a total turnover of 19 billion euros in 2021, BioNTech, today shared its first quarter data for the period January – March 2022. The company posted its highest quarterly revenue and profit to date. According to the information shared, the company made a total profit in the first three months of 2022. 6 billion 374 million euros turnover reaches. In the same period of 2021 this was 2 billion 48 million euros.

With the announcement, BioNTech shattered expectations of a $4 billion revenue announcement, if it’s your net profit 3.7 billion euros announced that. In the same period last year, this was 1.12 billion euros. The reason for the huge increase in BioNTech’s revenues was, of course, the revenue from the vaccine.

750 million doses of vaccine sold in the past 3 months:

While efforts are underway to gain herd immunity with vaccines around the world, BioNTech has increased the estimated yield of COVID-19 vaccines to $13 billion by 2022. increased to 17 billion euros† The company said it has signed agreements with Pfizer, its vaccine manufacturing partner, to distribute 2.4 billion doses to more than 100 countries this year and by the end of the first quarter. Billed 750 million doses of vaccine stated.

In addition to the financial situation, BioNTech is looking forward to its efforts to develop a vaccine for the Omicron variant in the coming weeks. laboratory data is obtained announced. Together with Pfizer on a vaccine that protects against the Omicron variant, the company started a trial in January.